HBIO vs. TMO, A, MTD, WAT, ILMN, TECH, BIO, CRL, BRKR, and PACB
Should you be buying Harvard Bioscience stock or one of its competitors? The main competitors of Harvard Bioscience include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), Bruker (BRKR), and Pacific Biosciences of California (PACB). These companies are all part of the "life sciences tools & services" industry.
Harvard Bioscience vs. Its Competitors
Harvard Bioscience (NASDAQ:HBIO) and Thermo Fisher Scientific (NYSE:TMO) are both life sciences tools & services companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.
In the previous week, Thermo Fisher Scientific had 74 more articles in the media than Harvard Bioscience. MarketBeat recorded 77 mentions for Thermo Fisher Scientific and 3 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.32 beat Harvard Bioscience's score of 0.06 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.
Harvard Bioscience presently has a consensus price target of $3.00, indicating a potential upside of 451.98%. Thermo Fisher Scientific has a consensus price target of $593.00, indicating a potential upside of 21.29%. Given Harvard Bioscience's higher possible upside, analysts plainly believe Harvard Bioscience is more favorable than Thermo Fisher Scientific.
Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.
Harvard Bioscience has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 9.5% of Harvard Bioscience shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Thermo Fisher Scientific has a net margin of 15.24% compared to Harvard Bioscience's net margin of -64.68%. Thermo Fisher Scientific's return on equity of 16.82% beat Harvard Bioscience's return on equity.
Summary
Thermo Fisher Scientific beats Harvard Bioscience on 13 of the 16 factors compared between the two stocks.
Get Harvard Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Harvard Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:HBIO) was last updated on 8/26/2025 by MarketBeat.com Staff